Inventor · disambiguated record
Jon Weidanz
Also filed as: WEIDANZ JON · WEIDANZ JON A
10 granted patents·32 pending applications·168 citations·filing 1999–2024
90Inventor score
Files withWEIDANZ JON A12ABEXXA BIOLOGICS INC11ALTOR BIOSCIENCE CORP5UNIV TEXAS3BOEHRINGER INGELHEIM INT2
Top patents by PatentIndex Score
42 records- 0191US10981996B1Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of useABEXXA BIOLOGIES INC·Filed 2020·Granted Apr 20, 2021·7 cites·12 claims
- 0290US11359023B2Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of useBOEHRINGER INGELHEIM PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·5 cites·12 claims
- 0390US10981997B1Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of useABEXXA BIOLOGICS INC·Filed 2020·Granted Apr 20, 2021·7 cites·13 claims
- 0489US7456263B2P53 binding T cell receptor moleculesALTOR BIOSCIENCE CORP·Filed 2002·Granted Nov 25, 2008·37 cites·23 claims
- 0586US7074904B2MHC complexes and uses thereofALTOR BIOSCIENCE CORP·Filed 2001·Granted Jul 11, 2006·34 cites·10 claims
- 0686US6534633B1Polyspecific binding molecules and uses thereofALTOR BIOSCIENCE CORP·Filed 1999·Granted Mar 18, 2003·53 cites·31 claims
- 0785US11976120B2Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of useBOEHRINGER INGELHEIM INT·Filed 2021·Granted May 7, 2024·1 cites·11 claims
- 0885US8105830B2Polyspecific binding molecules and uses thereofWEIDANZ JON A·Filed 2002·Granted Jan 31, 2012·23 cites·13 claims
- 0977US12173072B2Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of useBOEHRINGER INGELHEIM INT·Filed 2022·Granted Dec 24, 2024·0 cites·8 claims
- 1071US11971405B2Nanosensors and methods of making and using nanosensorsUNIV TEXAS·Filed 2018·Granted Apr 30, 2024·1 cites·20 claims
- 1168US2024255499A1Nanosensors and methods of making and using nanosensorsUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1266US2009233318A1Methods of assaying vaccine potencyWEIDANZ JON A·Filed 2009·Application pending·0 cites
- 1366US2024026007A1Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of useABEXXA BIOLOGICS INC·Filed 2021·Application pending·0 cites
- 1462US2009042285A1Antibodies at T cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2007·Application pending·0 cites
- 1561US2007092530A1Antibodies as T cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2006·Application pending·0 cites
- 1659US2014141455A1Methods of assaying vaccine potencyRECEPTOR LOGIC INC·Filed 2013·Application pending·0 cites
- 1757US2006034850A1Antibodies as T cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2005·Application pending·0 cites
- 1857US2023303701A1Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of useABEXXA BIOLOGICS INC·Filed 2021·Application pending·0 cites
- 1956US2021147572A1Antibodies and methods of use thereofABEXXA BIOLOGICS INC·Filed 2020·Application pending·0 cites
- 2056US2009304679A1Antibodies as T cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2009·Application pending·0 cites
- 2155US2012121577A1Antibodies as t cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2011·Application pending·0 cites
- 2254US2020325244A1Antibodies and methods of use thereofABEXXA BIOLOGICS INC·Filed 2020·Application pending·0 cites
- 2354US2009226474A1Antibodies as T cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2008·Application pending·0 cites
- 2453US2014065708A1Antibodies as t cell receptor mimics, methods of production and uses thereofRECEPTOR LOGIC LLC·Filed 2013·Application pending·0 cites
- 2552US2018086810A1T cell receptor fusions and conjugates and methods of use thereofALTOR BIOSCIENCE CORP·Filed 2017·Application pending·0 cites
- 2650US2024245721A1Double sided chimeric antigen receptor (car) engineered cell membrane based drug delivery systemsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2750US2012230995A1Polyspecific binding molecules and uses thereofWEIDANZ JON A·Filed 2011·Application pending·0 cites
- 2850US2013115191A1T cell receptor fusions and conjugates and methods of use thereofWEIDANZ JON A·Filed 2012·Application pending·0 cites
- 2947US2003144474A1T cell receptor fusions and conjugates and methods of use thereofSUNOL MOLECULAR CORP·Filed 2001·Application pending·0 cites
- 3047US2020291128A1Antibodies and methods of use thereofABEXXA BIOLOGICS INC·Filed 2020·Application pending·0 cites
- 3147US2009075304A1Methods of assaying vaccine potencyWEIDANZ JON A·Filed 2008·Application pending·0 cites
- 3246US2020291127A1Antibodies and methods of use thereofABEXXA BIOLOGICS INC·Filed 2020·Application pending·0 cites
- 3346US2007116718A1Fusion proteins comprising bacteriophage coat protein and asingle-chain T cell receptorALTOR BIOSCIENCE CORP·Filed 2006·Application pending·0 cites
- 3446US2020291116A1Antibodies and methods of use thereofABEXXA BIOLOGICS INC·Filed 2020·Application pending·0 cites
- 3545US2011293623A1Antibodies as t cell receptor mimics, methods of production and uses thereofWEIDANZ JON A·Filed 2011·Application pending·0 cites
- 3642US2020399377A1Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigenABEXXA BIOLOGICS INC·Filed 2019·Application pending·0 cites
- 3741US2003093818A1Transgenic animals comprising a humanized immune systemFiled 2001·Application pending·0 cites
- 3841US2021253713A1Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of useABEXXA BIOLOGICS INC·Filed 2019·Application pending·0 cites
- 3940US2019071502A1Methods and compositions for targeting a complex comprising non-classical hla-i and neoantigen in cancerABEXXA BIOLOGICS INC·Filed 2018·Application pending·0 cites
- 4038US2004253632A1Modulation of T -cell receptor interactionsSUNOL MOLECULAR CORP·Filed 2001·Application pending·0 cites
- 4137US2005282877A1Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockersBECKER BRYAN N·Filed 2005·Application pending·0 cites
- 4236US2016017031A1T cell receptor mimic rl9aRECEPTOR LOGIC LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jon Weidanz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →